Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination - Cheng, Samuel M. S.; Mok, Chris Ka Pun; Leung, Yonna W. Y.; Ng, Susanna S.; Chan, Karl C. K.; Ko, Fanny W.; Chen, Chunke; Yiu, Karen; Lam, Bosco H. S.; Lau, Eric H. Y.; Chan, Ken K. P.; Luk, Leo L. H.; et al. (Nature medicine, 2022)
Keywords: 631/250/2152/2153/1291; 631/250/590/1883; 631/250/590/2293; 631/326/596/4130; 692/699/255/2514; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Biomedical and Life Sciences; Biomedicine; BNT162 Vaccine; Brief Communication; Cancer Research; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; Homology; Humans; Infectious Diseases; Metabolic Diseases; Molecular Medicine; mRNA; mRNA Vaccines; Neurosciences; Neutralization; Neutralizing; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Vaccines, Synthetic; Viral diseases; Viruses